Online inquiry

IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13500MR)

This product GTTS-WQ13500MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SNCA gene. The antibody can be applied in Parkinson's disease (PD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000345.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6622
UniProt ID P37840
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13500MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1440MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ14069MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ8807MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ522MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ14782MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ2251MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ15662MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ3775MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY-1834942
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW